Tenpoint Therapeutics is a technology company.
Tenpoint Therapeutics has raised $155.0M across 2 funding rounds.
Tenpoint Therapeutics has raised $155.0M in total across 2 funding rounds.
Tenpoint Therapeutics has raised $155.0M in total across 2 funding rounds.
Tenpoint Therapeutics's investors include British Business Bank, EQT, Hillhouse Investment, Janus Henderson Investors, AdBio partners, Eight Roads Ventures, EQT Life Sciences, F-Prime, Qiming Venture Partners USA, Sofinnova Partners, Wille Finance, F-Prime Capital Partners.
Tenpoint Therapeutics is a global, clinical-stage biotechnology company developing innovative therapies to rejuvenate vision in aging eyes, targeting major ophthalmic conditions like presbyopia, cataracts, and geographic atrophy.[1][4][6] Its lead product, BRIMOCHOL™ PF, is a pupil-modulating therapeutic for presbyopia that has shown positive topline data from the Phase 3 BRIO-II pivotal study; the pipeline also includes TPT-161 to reverse cataract formation and TPT-005, an RPE cell replacement therapy for geographic atrophy.[1][3][4] The company serves patients with degenerative ocular diseases and eye care professionals, addressing unmet needs in vision restoration through engineered cell-based therapies and in vivo reprogramming, with strong growth from a 2023 merger of UK and US entities backed by investors like Sofinnova Partners and EQT.[2][3][4]
Tenpoint Therapeutics launched with a $70 million Series A financing to develop vision-restoring engineered cell-based therapeutics and in vivo reprogramming.[3] In July 2023, it formed through a strategic merger between Visus Therapeutics (US-based, with advanced assets like BRIMOCHOL™ PF) and the original UK-based Tenpoint Therapeutics (focused on early-stage cell therapies), creating a commercial-ready biotech with complementary capabilities.[4] This pivotal merger accelerated its pipeline, combining clinical-stage presbyopia treatments with regenerative approaches, supported by investors including Sofinnova Partners (as a founding lead) and EQT (entry in 2021).[2][3][4]
Tenpoint rides the wave of regenerative ophthalmology and aging population-driven demand for vision restoration, targeting massive markets like presbyopia (universal after age 40) and geographic atrophy.[1][4] Timing is ideal amid advances in cell therapies and gene editing, with market forces favoring differentiated, non-invasive options over glasses or surgery; its merger exemplifies consolidation for scale in biotech.[2][4] By translating academic innovations into commercial therapies, Tenpoint influences the ecosystem, accelerating engineered cell solutions and partnering with investors like Sofinnova to bridge early-stage research to global impact.[3]
Tenpoint is poised for commercialization of BRIMOCHOL™ PF post-Phase 3 success, expanding into a full eye care platform with cataract and atrophy therapies amid rising longevity trends.[3][4] Regulatory approvals and partnerships will shape its path, potentially disrupting ophthalmology with permanent vision fixes as AI-driven drug discovery and cell tech evolve. Its influence may grow by setting standards for rejuvenation biotech, building on merger momentum to lead aging-eye solutions and deliver sustained ecosystem value.[1][6]
Tenpoint Therapeutics has raised $155.0M across 2 funding rounds. Most recently, it raised $85.0M Series B in January 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 28, 2026 | $85.0M Series B | British Business Bank, EQT, Hillhouse Investment, Janus Henderson Investors | AdBio partners, Eight Roads Ventures, EQT Life Sciences, F-Prime, Qiming Venture Partners USA, Sofinnova Partners, Wille Finance |
| Jul 1, 2023 | $70.0M Series A | Eight Roads Ventures, F-Prime Capital Partners, INKEF Capital, Soffinova Partners, Two Sigma Ventures |